The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL

Rahul S. Bhansali(Hospital of the University of Pennsylvania), John D. Crispino(St. Jude Children's Research Hospital), Ji Heon Paul Lee(Lurie Children's Hospital), Thierry Besson(Centre National de la Recherche Scientifique), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Malini Rammohan(Northwestern University), Nobuko Hijiya(Lurie Children's Hospital), Sébastien Malinge(The Kids Research Institute Australia), Beat Bornhäuser(University Children's Hospital Zurich), Yi-Chien Tsai, Corinne Fruit(Centre National de la Recherche Scientifique)
Blood
November 29, 2018
10.1182/blood-2018-99-119854
Cited by 1

Related Papers

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
|Blood|2009|718
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
|Blood|2009|347
Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia
|JAMA|2007|314
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
|Journal of Clinical Investigation|2010|311
<i>IKZF1</i><sup>plus</sup>Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2018|304